Xanthogranulomatous cystitis (XC) is a rare benign chronic inflammatory disease of unknown etiology. Curative treatment of XC requires surgical resection, and most of reported cases were treated by partial cystectomy. Here we describe a case with XC that was treated using transurethral resection.
Introduction
Xanthogranulomatous changes, histologically characterized by the presence of lipid-laden macrophages, multinucleated giant cells, and cholesterol clefts, have been reported in many sites, 1 and the kidney is the most common site in the urinary tract. Xanthogranulomatous cystitis (XC) is a rare benign chronic inflammatory disease of unknown etiology. In this report, we describe a case with XC that was treated using transurethral resection.
Case presentation
A 64-year-old female presented with repeated cystitis. At presentation, she had no lower urinary tract symptoms or hematuria. She had a history of a pyelolithotomy for a right renal stone and a partial ureterectomy with an ureterovesiconeostomy for a right megaureter at the age of 30. Furthermore, she had a hysterectomy at the age of 50 and a laparoscopic cholecystectomy in the previous year. Physical examination was unremarkable, and laboratory data revealed a normal hematological and biochemical profile. Urinalysis revealed 0e5 red blood cells and 0e1 white blood cell per high power field. Urine culture grew coagulase-negative Staphylococcus, a-hemolytic Streptococcus, and Corynebacterium species. Urinary cytology showed no malignant cells. Ultrasonography revealed mild hydronephrosis in the right kidney, bilateral multiple renal cysts, and thickening of posterior bladder wall with no blood flow (Fig. 1 ). Her voiding function was normal with negligible post-void residual urine. Cystoscopy revealed a papillary mucosa at the posterior wall (Fig. 2) . Enhanced computed tomography demonstrated no stone or tumor in the right ureter and no appreciable change in the bladder. Magnetic resonance imaging revealed no urachal remnants. Cystoradiogram did not show vesicoureteral reflux.
Because the presence of bladder neoplasm could not be ruled out, an endoscopic resection was performed. Histological examination revealed a yellow-brown specimen, including many foamy macrophages that stained positive for CD68 (Fig. 3) , infiltrated neutrophils, and fibrosis in the submucosal layer. These histological findings led to the diagnosis of XC. There was no evidence of malignancy. The postoperative course was uneventful. The patient had no recurrence 10 months after the surgery. Discussion XC is a rare inflammatory disease that is microscopically characterized by multinucleated giant cells, lipid-laden macrophages (xanthoma cells), and cholesterol crystals, and macroscopically by soft yellow-brown plaques.
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Urology Case Reports j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / e u c r malignant bladder tumor, immunological disorders, abnormal lipid metabolism, and urethral stenosis. 1,3e5 In the kidney, xanthogranulomatous inflammation always develops as a consequence of an infection, which is often associated with urinary obstruction. In the present case, the XC may have been caused by repeated cystitis or retained suture materials. The location of XC was at the dome of the bladder in 18 of 28 cases, and 14 of the 28 cases were associated with an urachal lesion ( Table 1) . In the present case, the posterior wall of the bladder was involved, which indicates that there was no relationship with an urachus.
XC has no specific clinical manifestations; therefore, it is difficult to distinguish from other bladder diseases, such as carcinoma. The main symptoms were lower abdominal palpable mass, cystitis-like symptoms, discharge from the umbilicus, and painless macrohematuria. Therefore, the diagnosis of XC is usually based on pathological examinations.
Curative treatment of XC requires surgical resection, 3 and no postoperative recurrence has been reported. Of the 28 published cases, the treatment measure was partial resection in 22 cases, transurethral resection in four cases including the present case, total cystectomy in one case, and augmentation cystoplasty for a small capacity bladder after the exclusion of neoplasm in one case. The use of transurethral resection to treat XC was reported only in recent years, 5 possibly because of early detection via imaging tests.
Transurethral resection appears to be a minimally invasive and curative treatment for small XC lesions.
Conclusion
XC is a rare benign chronic inflammatory disease. Curative treatment of XC requires surgical resection, and a partial cystectomy has been applied in most cases. The present case suggests that a transurethral resection is a minimally invasive and curative treatment for small XC lesions.
